-
Je něco špatně v tomto záznamu ?
Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia
A. Nagler, M. Labopin, B. Dholaria, F. Ciceri, A. Fraccaroli, D. Blaise, R. Fanin, B. Bruno, E. Forcade, J. Vydra, P. Chevallier, CE. Bulabois, P. Jindra, M. Bornhäuser, J. Canaani, J. Sanz, BN. Savani, A. Spyridonidis, S. Giebel, E. Brissot, A....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- akutní myeloidní leukemie * genetika MeSH
- chronická nemoc MeSH
- cytogenetické vyšetření MeSH
- haploidentická transplantace MeSH
- lidé MeSH
- nemoc štěpu proti hostiteli * MeSH
- recidiva MeSH
- transplantace hematopoetických kmenových buněk * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Baseline cytogenetics and disease status are key factors predicting the outcomes of allogeneic hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML). The importance of cytogenetic risk in patients with primary refractory or relapsed (R/R) AML undergoing haploidentical (Haplo) HCT is unknown. We studied the impact of cytogenetic risk in patients with R/R de novo AML with active disease who underwent non-T-cell-depleted Haplo-HCT with post-transplantation cyclophosphamide from 2010 to 2020. Four hundred forty patients with active disease at transplantation from the European Society for Blood and Marrow Transplantation database were analyzed (291 [66.1%] with intermediate-risk [AMLint] and 149 [44.1%] with adverse-risk cytogenetics [AMLadv]). Impact of baseline cytogenetic risk on various transplantation outcomes was evaluated. Pre-transplantation disease status was relapse in 48.1% and 26.8% and primary refractory in 51.9% and 73.2% of the patients with AMLint and AMLadv, respectively (P < .0001). Two-year leukemia-free survival (LFS, 35.5% versus 15.5%, P = .001) and overall survival (OS, 39.2% versus 20.1%, P = .001) were better in AMLint versus AMLadv. In multivariate analysis, the relapse rate was significantly higher (hazard ratio [HR] = 2.17 [95% confidence interval {CI} 1.57-3.0]) and LFS (HR = 1.71 [95% CI, 1.31-2.22]) and OS (HR = 1.69 [95% CI, 1.29-2.22]), significantly lower for patients with AMLadv compared to AMLint, conditioning intensity did not affect leukemia relapse rate. Non-relapse mortality (HR = 1.1 [95% CI, 0.7-1.74]) and graft-versus-host disease-free, relapse-free survival (HR = 1.37 [95% CI, 1.06-1.77]) did not differ significantly between the risk groups. Disease status before transplant (primary refractory versus relapsed) or conditioning intensity did not impact main transplant outcomes. Baseline cytogenetic risk remains a key prognostic factor for patients with R/R AML with persistent disease before non-T-cell-depleted Haplo-HCT.
ALWP of the EBMT Paris office Paris France
Azienda Ospedaliero Universitaria di Udine Division of Hematology Udine Italy
Charles University Hospital Dept of Hematology Oncology Pilsen Czech Republic
CHU Bordeaux Hôpital Haut Leveque Pessac France
CHU Grenoble Alpes Université Grenoble Alpes Service d`Hématologie Grenoble France
CHU Nantes Dept D`Hematologie Nantes France
Division of Hematology Sheba Medical Center Tel Hashomer Israel
Hematology Department Hospital Clinic Barcelona Spain
Hematology Stem Cell Transplant Unit School of Medicine University of Patras Patras Greece
Institute of Hematology and Blood Transfusion Prague Czech Republic
IRCCS San Raffaele Hospital University Vita Salute Milano Italy
Sheba Medical Center Faculty of Medicine Tel Aviv University Tel Aviv Israel
Universitaetsklinikum Dresden Medizinische Klinik und Poliklinik 1 Dresden Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032870
- 003
- CZ-PrNML
- 005
- 20240528145601.0
- 007
- ta
- 008
- 230120s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jtct.2022.08.018 $2 doi
- 035 __
- $a (PubMed)36031079
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Nagler, Arnon $u Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel
- 245 10
- $a Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia / $c A. Nagler, M. Labopin, B. Dholaria, F. Ciceri, A. Fraccaroli, D. Blaise, R. Fanin, B. Bruno, E. Forcade, J. Vydra, P. Chevallier, CE. Bulabois, P. Jindra, M. Bornhäuser, J. Canaani, J. Sanz, BN. Savani, A. Spyridonidis, S. Giebel, E. Brissot, A. Bazarbachi, J. Esteve, M. Mohty
- 520 9_
- $a Baseline cytogenetics and disease status are key factors predicting the outcomes of allogeneic hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML). The importance of cytogenetic risk in patients with primary refractory or relapsed (R/R) AML undergoing haploidentical (Haplo) HCT is unknown. We studied the impact of cytogenetic risk in patients with R/R de novo AML with active disease who underwent non-T-cell-depleted Haplo-HCT with post-transplantation cyclophosphamide from 2010 to 2020. Four hundred forty patients with active disease at transplantation from the European Society for Blood and Marrow Transplantation database were analyzed (291 [66.1%] with intermediate-risk [AMLint] and 149 [44.1%] with adverse-risk cytogenetics [AMLadv]). Impact of baseline cytogenetic risk on various transplantation outcomes was evaluated. Pre-transplantation disease status was relapse in 48.1% and 26.8% and primary refractory in 51.9% and 73.2% of the patients with AMLint and AMLadv, respectively (P < .0001). Two-year leukemia-free survival (LFS, 35.5% versus 15.5%, P = .001) and overall survival (OS, 39.2% versus 20.1%, P = .001) were better in AMLint versus AMLadv. In multivariate analysis, the relapse rate was significantly higher (hazard ratio [HR] = 2.17 [95% confidence interval {CI} 1.57-3.0]) and LFS (HR = 1.71 [95% CI, 1.31-2.22]) and OS (HR = 1.69 [95% CI, 1.29-2.22]), significantly lower for patients with AMLadv compared to AMLint, conditioning intensity did not affect leukemia relapse rate. Non-relapse mortality (HR = 1.1 [95% CI, 0.7-1.74]) and graft-versus-host disease-free, relapse-free survival (HR = 1.37 [95% CI, 1.06-1.77]) did not differ significantly between the risk groups. Disease status before transplant (primary refractory versus relapsed) or conditioning intensity did not impact main transplant outcomes. Baseline cytogenetic risk remains a key prognostic factor for patients with R/R AML with persistent disease before non-T-cell-depleted Haplo-HCT.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a haploidentická transplantace $7 D000075442
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 12
- $a akutní myeloidní leukemie $x genetika $7 D015470
- 650 12
- $a nemoc štěpu proti hostiteli $7 D006086
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a chronická nemoc $7 D002908
- 650 _2
- $a cytogenetické vyšetření $7 D020732
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Labopin, Myriam $u Sorbonne University, Sevice d'hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France; ALWP of the EBMT Paris office, Paris, France
- 700 1_
- $a Dholaria, Bhagirathbhai $u Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: Bhagirathbhai.r.dholaria@vumc.org
- 700 1_
- $a Ciceri, Fabio $u IRCCS San Raffaele Hospital, University Vita-Salute, Milano, Italy
- 700 1_
- $a Fraccaroli, Alessia $u Hematopoietic Stem Cell Transplantation, Department of Internal Medicine III, University Hospital, Munich, Germany
- 700 1_
- $a Blaise, Didier $u Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France
- 700 1_
- $a Fanin, Renato $u Azienda Ospedaliero Universitaria di Udine, Division of Hematology, Udine, Italy
- 700 1_
- $a Bruno, Benedetto $u S.S.C.V. D Trapianto di Cellule Staminali A.O.U Citta della Salute e della Scienza di Torino, Torino, Italy
- 700 1_
- $a Forcade, Edouard $u CHU Bordeaux, Hôpital Haut-Leveque, Pessac, France
- 700 1_
- $a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Chevallier, Patrice $u CHU Nantes, Dept. D`Hematologie, Nantes, France
- 700 1_
- $a Bulabois, Claude Eric $u CHU Grenoble Alpes - Université Grenoble Alpes, Service d`Hématologie, Grenoble, France
- 700 1_
- $a Jindra, Pavel $u Charles University Hospital, Dept. of Hematology/Oncology, Pilsen, Czech Republic
- 700 1_
- $a Bornhäuser, Martin $u Universitaetsklinikum Dresden Medizinische Klinik und Poliklinik I, Dresden, Germany
- 700 1_
- $a Canaani, Jonathan $u Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- 700 1_
- $a Sanz, Jaime $u Hospital La Fe, Valencia, Spain
- 700 1_
- $a Savani, Bipin N. $u Vanderbilt University Medical Center, Nashville, Tennessee $7 xx0317726
- 700 1_
- $a Spyridonidis, Alexandros $u Hematology Stem Cell Transplant Unit, School of Medicine, University of Patras, Patras, Greece
- 700 1_
- $a Giebel, Sebastian $u Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
- 700 1_
- $a Brissot, Eolia $u Sorbonne University, Sevice d'hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France
- 700 1_
- $a Bazarbachi, Ali $u Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
- 700 1_
- $a Esteve, Jordi $u Hematology Department, Hospital Clinic, Barcelona, Spain
- 700 1_
- $a Mohty, Mohamad $u Sorbonne University, Sevice d'hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France; ALWP of the EBMT Paris office, Paris, France $7 xx0317729
- 773 0_
- $w MED00208298 $t Transplantation and cellular therapy $x 2666-6367 $g Roč. 28, č. 11 (2022), s. 773.e1-773.e8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36031079 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20240528145558 $b ABA008
- 999 __
- $a ok $b bmc $g 1891550 $s 1184205
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 28 $c 11 $d 773.e1-773.e8 $e 20220827 $i 2666-6367 $m Transplantation and cellular therapy $n Transplant Cell Ther $x MED00208298
- LZP __
- $a Pubmed-20230120
